# RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF

Study · id `cardio:ct-nct07696975` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07696975](<https://clinicaltrials.gov/study/NCT07696975>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07696975

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT07696975. Randomized; quadruple masking; primary purpose treatment. Start 2027-07-01 (anticipated); primary completion 2030-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT07696975, source copy `cardio:ctgov-nct07696975-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2027-07-01 (anticipated) (ClinicalTrials.gov record NCT07696975, source copy `cardio:ctgov-nct07696975-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2030-07-31 (anticipated) (ClinicalTrials.gov record NCT07696975, source copy `cardio:ctgov-nct07696975-2026-11-06`, retrieved 2026-11-18)
- Completion: 2032-07-31 (anticipated) (ClinicalTrials.gov record NCT07696975, source copy `cardio:ctgov-nct07696975-2026-11-06`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07696975-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
- Acronym: RELIEVE-HFrEF
- Condition: Heart Failure and Reduced Ejection Fraction
- Condition: Heart Failure Chronic
- Condition: Heart Failure New York Heart Association Class III
- Condition: Heart Failure Congestive
- Intervention (Device): Implantation of the V-Wave Interatrial shunt
- Intervention (Device): Sham (no implant)
- Lead sponsor: V-Wave Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Johnson & Johnson
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as a collaborator: Johnson & Johnson (`cardio:org-johnson-johnson`)

## Provenance

Content hash: 6cdd43e3f61bc5bf90a20c5e0eca724eade105f41fbd43f9a9f18dad160d8037
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
